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Introduction
Loop diuretics, such as furosemide and torasemide, are used for symptomatic fluid control in patients with chronic heart failure (CHF) [1] . Both diuretics exert similar diuretic effects [2, 3] but their effect on clinical outcomes remains uncertain. Interestingly, previous studies have reported that torasemide -but not furosemide -decreased collagen volume fraction in the hearts of patients with chronic heart failure (CHF) [4] , and early evidence suggests that torasemide treatment was associated with lower mortality compared to furosemide in the TORasemide In Chronic heart failure (TORIC) study [5] .
Myocardial fibrosis is a hallmark of both left ventricular dysfunction and of atrial arrhythmogenic structural remodeling [6] [7] [8] which represents an important substrate for atrial fibrillation (AF) [9] . An important mediator of left ventricular and atrial fibrosis is the activation of mineralocorticoid receptors (MR) by aldosterone [10] [11] [12] [13] [14] [15] . Interestingly, experimental and human studies have reported that torasemide, but not furosemide, may exert anti-aldosterone effects [16] [17, 18] . However, the underlying mechanisms and the consequences of these observations are only partially understood, especially in the context of atrial fibrillation.
Our previous studies found that the fibrosis in left atria of patients with AF is characterized by increased angiotensin II tissue concentrations as well as increased expression and activity of the small Rho-GTPase Rac1, increased expression of the connective tissue growth factor (CTGF) and increased expression of lysyl oxidase (LOX), a key enzyme of collagen crosslinking [19] [20] [21] [22] [23] , as well as micro RNA-21 (miR-21), a regulator of ventricular [24] and atrial fibrosis [25] . This pro-fibrotic signalling pathway can be activated by aldosterone [26] .
Based on these findings, the present study was undertaken to test the hypothesis of a potential differential effect of the loop-diuretics torasemide and furosemide on myocardial fibrosis and atrial remodelling and to characterize the underlying signalling events. To this end, cultured primary cardiac cells and Rac1 transgenic mice were studied that spontaneously develop atrial fibrosis and atrial fibrillation with aging.
Materials and Methods

Cell Isolation and Culture
Cardiomyocytes and cardiac fibroblasts were isolated from the atria and the ventricles of 5 days old neonatal Sprague-Dawley rat hearts [27] . Purity of fibroblasts was confirmed by vimentin staining. After 48 h in culture, myocytes exhibited regular spontaneous contractions. The primary cells were used for experiments after 3-6 days of culture.
HL-1 cells, a cardiac muscle cell line from the AT-1 mouse atrial cardiomyocyte tumor lineage, were a gift from William C. Claycomb, Ph.D.; Professor of Biochemistry and Molecular Biology LSU Health Sciences Center; New Orleans) [50] . HL-1 cells maintain the ability to contract and retain differentiated cardiac morphological, biochemical, and electrophysiological properties [50] .
Ventricular rat neonatal cells were used for the signalling experiments, the results were confirmed using pooled atrial neonatal cardiomyocytes and fibroblasts as well as HL-1 cells.
Animal Studies
Mice with cardiac overexpression of constitutively active (V12) Rac1 under the control of the α-myosin heavy chain (MHC) promoter (RacET) and wild type controls (WT; FVB-N-strain)
promoter [28] were fed with normal chow (ssniff, Germany) or normal chow supplemented with 10 mg/kg/d of commercially available torasemide (Meda Pharma, Germany) or 40mg/kg/d furosemide (STADA, Germany) for 8 months. Heart rate, regularity and presence of p-waves were documented by ECG (Picker, Schwarzer CU 12 system) under anaesthesia with ketamine (ketavet, 100mg/kgKG) and xylazine (rompun, 10mg/kgKG) ip. Transthoracic echocardiography (Vevo 770® high-resolution imaging system (Visual Sonics, Canada) with a center frequency of 30 MHz and a focal depth of 12.6mm) was performed in all mice under anaesthesia with ketamine (ketavet, 100mg/kgKG) and xylazine (rompun, 10mg/kgKG) ip; fractional shortening (FS), enddiastolic thickness of interventricular septum (IVSd) and the left posterior wall (LPWd) as well as the left ventricular enddiastolic diameter (LVDd) were taken. The characteristics of the mice are depicted in Table 1 . None of the wildtype mice exhibited atrial arrhythmias [19, 20, 29] .
The study was approved by the animal ethics committee of the Universität des Saarlandes and is in accord with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Pub. No. 85-23, revised 1996). The study was not funded by the pharmaceutical industry.
Reverse-transcriptase polymerase-chain reaction (RT-PCR)
Total RNA isolation, reverse transcription, and competitive PCR was performed according to standard techniques. The sense, (5'-GATATCTTCAAAAGAGAGG -3') and anti-sense (5'-TACTGTTCAGCTAATCACG -3') primers were used to amplify a CYP11B2 cDNA and (5'-TACTGTTCAGCTAATCACG -3') and anti-sense (5'-TACTGTTCAGCTAATCACGC -3') primers were used to amplify a MCR cDNA fragment. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was amplified as an external standard. Each PCR cycle consisted of denaturing at 94°C for 30 s, annealing at 53°C for 30 s, and elongation at 72 °C for 60 s. The linear exponential phases for CYP11B2, MCR and GAPDH PCR were 40 and 22 cycles, respectively. Equal amounts of corresponding CYP11B2, MR and GAPDH RT-PCR products were loaded on 1.5% agarose gels and optical densities of ethidium-bromide stained DNA bands were quantitated.
Micro-RNA Isolation and RT-PCR
MicroRNAs were isolated by a miRNA isolation kit (mirVana, Ambion). For real-time PCR, a target-specific stem loop structure and reverse transcription primers were used. After reverse transcription miR-21 expression was quantified with specific TaqMan hybridization probes (TaqMan miR-21 microRNA assay, Applied Biosystems). The small RNA molecule U6 small nuclear (Rnu6-2) was amplified as a control.
Western Analysis
Protein lysates were prepared as described [27] . Immunoblotting was performed using AntiRac1 (Rac1, Upstate, clone 23A8), CTGF (sc-14939, Santa Cruz; USA), LOX (ab31238, Abcam, UK) and GAPDH (ab8245, Abcam; UK). Immunodetection was accomplished using goat anti-rabbit or goat anti-mouse secondary antibody (1:4000 dilution, Sigma) and an enhanced chemiluminescence kit (Amersham) followed by densitometry.
Rac1 GST-PAK Pull-Down Assay
Pull-down assays were performed using agarose labelled PAK-1 fusion protein (Upstate, USA) as described (4).
CYP11B2 Activity
The untransfected V79MZ Chinese hamster cells (provided by Prof. Bernhardt, Saarland University) and the human CYP11B2 expressing V79MZ cell line were grown as monolayer culture in Dulbecco's modified Eagle medium (DMEM; c.c.pro, Oberdorla, Germany) supplemented with 5 % of fetal calf serum (FCS;Sigma), penicillin (100 U/ml), streptomycin (100 µg/ml), glutamine (2 mM) and sodium pyruvate (1 mM) at 37°C in 5 % CO 2 in air. 
Quantification of aldosterone concentrations
The left atrial (LA) tissues samples from FVBN-mice, RacET-mice, RacET-mice (fed with torasemide or furosemide) were weighed and homogenized in 500 µl PBS. The protein content was determined using Bradford reagent followed by extraction of aldosterone from homogenates with 1 ml ethyl acetate. The homogenate was vortexed for 15 min and using the aldosterone HTRF assay kit from Cisbio Bioassays, France.
Nuclear receptor reporter assay
Human mineralocorticoid receptor activity was assessed using a luciferase reporter gene assay kit (INDIGO Biosciences, State College, PA, USA) according to the manufacturer´s instructions. Reporter cells were dispensed into wells of the assay plate and were then immediately dosed with torasemide, furosemide, SL242 and NSC as indicated in the results section. Following overnight incubation, treatment media were discarded and luciferase detection reagent was added. The intensity of light emission from each sample well was quantified using a plate-reading luminometer.
Histological Analyses
10 µm cryo-sections were stained with 0.1% Sirius Red F3BA (Polysciences). Lucia Measurement Version 4.6 software was used for quantification of interstitial fibrosis.
Measurement of Hydroxyprolin
Hydroxyproline concentrations in the supernatants of cultured cardiac fibroblasts were determined by enzyme-linked immunosorbent assay using a hydroxyproline assay kit (Quickzyme, The Netherlands).
Statistical Analysis
Band intensities were analysed by densitometry. Mean, standard error of the mean (SEM) and statistical analyses were calculated using Sigma Plot 12.3 software version 2.0. For multiple comparisons, ANOVA followed by Newman-Keuls post-hoc analysis for multiple comparisons was applied. The Fisher exact test was used to compare the prevalence of AF (Graph Pad Priss 5 software). Differences were considered significant at p<0.05.
Results
Torasemide Reduces CTGF-, LOX-and miR-21 Expression in Cardiac Fibroblasts
Western Blot analysis of neonatal cardiac fibroblasts treated with torasemide or furosemide 
Torasemide Reduces CYP11B2 Activity
In order to characterize the underlying cellular mechanism, we investigated the effect of torasemide and furosemide treatment (50 µM, 24 hours) on the mineralocorticoid receptor (MR) and the aldosterone synthase (CY11B2) expression in cardiac fibroblasts. Both loop diuretics did not alter the MR expression. Similarly, luciferase reporter gene assays showed no change of the activity of the MR. Furthermore, the mRNA expression of CYP11B2 was not changed by either one of the two loop diuretics (Figure 2 A-E).
CYP450 inhibitors typically contain nitrogen-containing aliphatic or aromatic functions.
Therefore, we hypothesized that torasemide may have an inhibitory effect on aldosterone synthase and that furosemide would not inhibit CYP11B2, as it contains not heterocyclic nitrogen. To test the inhibition of torasemide on CY11B2 activity, lung fibroblasts (V79MZ cells) that exhibit no endogenous CYP450 activity underwent stable transfection with human aldosterone synthase (CYP11B2) and were treated with torasemide. These experiments showed that torasemide 50 µM potently reduces CYP11B2 activity by 75±1.8% (p<0.05) compared to untreated control. In contrast, furosemide 50 µM as well as higher concentrations had no effect on CYP11B2 activity (Figure 2 F) . Since 50µM torasemide exerted the greatest reduction of CYP11B2 activity, this concentration was used for further in vitro experiments.
Selective Inhibition of CYP11B2 reduces Expression of CTGF, LOX, miR-21 and Collagen Content in Cardiac Fibroblasts
Recently, we developed aldosterone synthase inhibitors with improved activity and selectivity against other steroidogenic enzymes such as CYP11B1, CYP17 and CYP19 as well as hepatic cytochrome P450 enzymes (CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6 and CYP3A4) [31] [32] [33] . Therefore we studied the effect of specific inhibition of CYP11B2 by using the novel selective inhibitor SL 242 (for detailed information see compound 7 from To test the effect of selective CYP11B2 inhibition, cardiac fibroblasts were stimulated with angiotensin II (Ang, 1µM; 3 hours) and pre-incubated with or without the CYP11B2 specific inhibitor SL 242 [34] . Ang+SL242 118±23%, p<0.05), whereas MCR activity quantified by MR nuclear translocation and luciferase reporter gene assay was unaffected (Figure 3 A-G) .
Torasemide Reduces CTGF Expression without Affecting Rac1 Activity in Cardiomyocytes
To further study the underlying mechanisms, neonatal cardiomyocytes were treated with torasemide and furosemide (50 µM, 24 hours) and expression of CTGF and Rac1 as well as 
Torasemide Reduces Myocardial Aldosterone Concentration, Atrial Fibrosis and Atrial Fibrillation in vivo
To characterize the interaction of aldosterone synthase inhibition and CTGF, LOX, Rac1, miR-21 and atrial fibrosis during AF in vivo, transgenic mice with cardiac overexpression of constitutively active (V12) Rac1 under the control of the αMHC promoter (RacET) were studied because these mice develop spontaneous AF at high age [19] [20] [21] 25] . RacET mice were treated long-term with torasemide (10mg/kg/day) or furosemide (40mg/kg/day) for 8 months. Furosemide was used at a higher concentration because the diuretic potency of torasemide is known to be 4 fold higher than furosemide [2, 3, 35] . Pilot experiments had shown that these doses yield similar urine output in mice.
The characteristics of the mice are depicted in table 1. Both diuretics exerted similar effects on urine output, but renal sodium, potassium and calcium output were increased in furosemide treated mice compared to untreated or torasemide treated RacET, whereas serum electrolyte levels were unaffected. Blood pressure, left ventricular function and left atrial size were comparable between the treated animals.
WT and untreated RacET exhibited similar serum aldosterone levels, whereas torasemid treatment showed a non-significant trend towards reduced and furosemide a non-significant trend towards increased serum aldosterone levels ( 
Discussion
The data identify the aldosterone synthase (CYP11B2) as a key regulator of fibrotic remodeling during atrial fibrillation. Aldosterone synthase regulates miR-21 via the profibrotic mediators connective tissue growth factor and lysyl oxidase down-stream of Rac1
GTPase. The loop diuretic torasemide reduces aldosterone synthase activity and prevents atrial fibrosis and atrial fibrillation in mice.
Aldosterone synthase (CYP11B2) catalyses the three terminal steps in the biosynthesis of the mineralocorticoid aldosterone [36] . It is the only enzyme capable of synthesizing aldosterone in humans. CYP11B2 is a mitochondrial cytochrome P450 enzyme which is located in the inner mitochondrial membrane, mainly in the Zona glomerulosa of the adrenal cortex and to a much lesser extend in the myocardium [37] [38] [39] [40] . Here, our data confirm the expression and functional role of CYP11B2 in cardiac myocytes and in cardiac fibroblasts [41] . By binding to epithelial mineralocorticoid receptors (MR), aldosterone plays an important role regulating sodium and water retention as well as potassium secretion. In addition, the MR is a direct regulator of left ventricular myocardial remodeling [42] . Aldosterone release is triggered by angiotensin-II, the extracellular potassium concentration and adrenocorticotropic hormones [43, 44] . Aldosterone directly contributes to the pathogenesis of fibrosis and AF [10-15, 26, 38] . The small GTPase-Rac1, which contributes to the generation of reactive oxygen species (ROS) by coupling to NOX1 [45] , the connective tissue growth factor, the lysyl oxidase and miR-21 contribute to the aldosterone-induced signal transduction during the pathogenesis of atrial remodeling [19] [20] [21] 25 ] + [26] . Here, the experiments in primary cardiac fibroblasts and 37.2%, p < 0.00017) and that fewer patients receiving torsemide died (2.2% vs. 4.5%, p < 0.05) [5] . Additionally, a recent meta-analysis suggests improved functional status and mortality with torsemide compared with furosemide [46] .
A crucial point in the development of any CYP inhibitor is selectivity. This is especially true of CYP11B2 since the inhibitors must not affect 11β hydroxylase (CYP11B1), which is the key enzyme of glucocorticoid biosynthesis. Selectivity towards aldosterone synthase is not easy to reach, because CYP11B1 and CYP11B2 exhibit a sequence homology of 93%. SL242
is a non-steroidal compound in order to minimize the risk of side effects caused by interaction with steroid receptors or other steroidogenic enzymes and is the only compound, which is able to inhibit human CYP11B2 to 94% [0.5 µM] and rat CYP11B2 to 65% [2 µM] [34] . Thus, SL242 is a suitable tool for studies in disease-oriented models as described in this paper.
Indeed, the data show that CY11B2 inhibition by SL 242 completely prevented angiotensin II induced CTGF, LOX and miR-212 expression as well as angiotensin II induced fibrosis, without affecting MR activity.
To further assess the relation of myocardial Rac1, aldosterone synthase and atrial fibrosis and atrial fibrillation in vivo, transgenic mice over-expressing Rac1 under the control of the MHC promoter which develop atrial fibrillation at older age [19] [20] [21] 29] were treated for 8 months with torasemide or furosemide [2, 3, 35] . Both diuretics exerted similar effect on urine output as well as on blood pressure, left ventricular function and left atrial size (Table 1 ; [2, 3] ). The main novel finding of the experiment is that only torasemide-treated animals exhibited a reduction in atrial fibrosis. Importantly, this finding correlated with a marked reduction of the phenotype of spontaneous atrial fibrillation.
The RacET mice are characterized by up-regulation of CTGF, LOX, miR-21 and fibrosis in the left atrium. Furthermore, RacET mice exhibit a marked increase of myocardial aldosterone tissue concentrations, which was completely prevented by torasemide-but not by furosemide treatment. Compared to their wildtypes, RacET mice show similar aldosterone serum-but increased myocardial aldosterone concentrations which were reduced by torasemide. This finding may be explained by the reported ability of torasemide to reduce trans-cardiac extraction of circulating aldosterone [47] and/or by the direct inhibition of aldosterone synthase activity. The data are in agreement with previous studies reporting that torasemide is not an MR antagonist [41] but reduces the expression of aldosterone synthase and fibrosis in the left ventricles of rats with dilated cardiomyopathy [35, 48] as well as the incidence of atrial fibrillation in patients with dilated cardiomyopathy [49] . Importantly and consistently, the regulation e.g. of LOX and CTGF was identical in neonatal atrial fibroblasts and cardiomyocytes compared to the ventricular fibroblasts as well as in HL-1 cells (Supplement Figure 2) . In our study, cultured cells are applied to obtain mechanistic insight by enhancing and inhibiting specific steps in the signal cascade. However, in order to gain information about the in vivo situation, the mouse model was studied. For future experiments, inhibition of CYP11B2 in vivo by SL 242 would be of interest. However, the specific CYP11B2 inhibitors show high species selectivity and SL242 may be specific for rat and humans but not mice. In addition, the synthesis of the amount of SL242 needed for the long term in vivo studies represents a challenge. SL242 was therefore used for the mechanistic experiments to explain the observations obtained with torasemide, which has the advantage to be widely available including clinical use. Clearly, our data support the concept of studying novel inhibitors of aldosterone synthase in humans [51] .
Conclusion
In summary, torasemide but not furosemide reduces aldosterone synthase mediated profibrotic signalling, which induces miR-21 expression, CTGF and LOX. These mechanistic studies set the stage to evaluate the effects of aldosterone synthase inhibition on atrial remodeling in humans. The improved understanding of the signalling during atrial fibrosis may help to identify novel therapeutic targets such as the aldosterone synthase.
Perspectives
The prognostic effect of loop diuretics may differ between torasemide and furosemide. Only torasemide reduces aldosterone synthase mediated pro-fibrotic signalling in mice and prevents atrial fibrillation. These mechanistic studies set the stage to evaluate the effects of torasemide and of aldosterone synthase inhibition on atrial remodeling in humans.
.
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